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Objective: The aim of this study is to evaluate our surgical experience with intracranial
meningiomas in NF2 patients and provide knowledge of the natural history of these lesions.
Methods: We included in the natural growth study patients with the diagnosis of NF2 who
harbored intracranial meningiomas and were observed for at least 1 year. Tumors that were
resected before achieving long-term follow-up were excluded from this analysis.
Results: We found 118 intracranial meningiomas in 34 patients in our series. 8 meningiomas
in 7 patients were symptomatic. It was found that with an increase in tumor volume, brain
edema and with the tumor location at the skull base, meningiomas are more likely to be
symptomatic. Univariate analysis revealed that tumor growth was associated with a
younger age at the onset of NF2-related symptoms, greater initial tumor volume, brain
edema and with the presence of intracranial non-vestibular schwannoma. Multivariate
analysis showed that the probability of tumor growth is associated with prolonged follow-up
time. De novo meningiomas exhibited a signiﬁcantly higher growth rate than other menin-
giomas. These tumors were more frequent in patients with intracranial non-vestibular
schwannoma and with increasing length of meningioma observation.
Conclusion: Meningiomas occur in about half NF2 patients. Many of them exhibit slow
growth and long remain asymptomatic, however, those associated with early onset of
NF2 symptoms and other features of the disease severity should be monitored in case of
clinical and radiological progression that may require surgical treatment.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Neuroﬁbromatosis type 2 is an autosomal dominant syndrome
predisposing to multiple benign tumors of the central and
peripheral nervous system. The hallmark of this disease is the* Corresponding author at: Klinika Neurochirurgii, Warszawski Uniwe
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occurs in 90–95% of patients [1–3]. Meningiomas are the
second most frequent tumor type in NF2. They are often
multiple [1–3] and occur in about half of these patients [4].
They develop at a younger age than their counterparts with
sporadic cases of meningiomas [2,3,5]. In the pediatric agersytet Medyczny, ul. Banacha 1a, 02-097 Warszawa, Poland.
p. z o.o. All rights reserved.
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Furthermore NF2 is diagnosed in 10–29% of children present-
ing with meningioma [7–10]. Meningiomas associated with
NF2 frequently show aggressive features on pathological
examination [11,12]. A higher proliferative potential of NF2
meningiomas, however, is observed in tumors requiring
surgery while remaining slow-growing lesions are probably
less aggressive nature [13]. Meningiomas in NF2 patients are
associated with disease severity as risk of mortality is 2.5-fold
greater in people with meningiomas compared to those
without such lesions [14].
Yet little is known about long-term natural history of
meningiomas in NF2 patients. Data about meningioma
surgery in NF2 are sparse in the literature. Knowledge of
meningiomas behavior in NF2 patients should be determined
for their optimal management, including timing of surgical
treatment. The aim of this study is to evaluate our surgical
experience with intracranial meningiomas in NF2 patients and
provide knowledge of natural history of these lesions. We
sought to deﬁne whether meningiomas are a major problem in
the treatment of patients with NF2, and whether we can safely
observe meningiomas in these patients. We assessed clinical
characteristics, new tumor development, surgical outcome
and growth patterns of meningiomas in NF2 patients with
long-term clinical and radiographic follow-up. Furthermore
we compare NF2 patients with intracranial meningiomas to
those without to identify differences between the two patient
subgroups.
2. Materials and methods
2.1. Patient population
Thirty four patients with neuroﬁbromatosis type 2, as deﬁned
on the basis of the modiﬁed National Institute of Health (NIH)
Consensus Panel Criteria [15], were surgically treated at our
institution between 1998 and 2014. We have retrospectively
reviewed the clinical records, neuroimaging studies, and
follow-up data of the treated patients. Among 34 patients,
13 had no intracranial meningiomas and 21 had one or
multiple intracranial meningiomas. We included in the
natural growth study patients with the diagnosis of NF2
who harbored intracranial meningiomas and were observed
for at least 1 year. Tumors that were resected before achieving
long-term follow-up were excluded from this analysis. Two
meningiomas were resected at another institution and were
not included in the study. Another 3 tumors were excluded
from growth rate analysis given their short follow-up before
resection. A total of 118 meningiomas in 21 patients met the
inclusion criteria and were suitable for growth rate analysis.
Resected tumors were graded according to the WHO 2000 and
the WHO 2007 [16] grading scheme. All patients had a clinical
examination and brain MRI study performed at least once a
year.
2.2. Tumor measurements.
The T1-weighted multiplanar images with gadolinium en-
hancement were used for volume measuring. Tumor volumeswere determined manually using the 3-diameters technique
V = (D1  D2  D3)/2 [17]. Multilobulated tumors were divided
into individual compartments and tumor volumes of these
components were then summed. 3D MRI sequences for the
calculation of exact changes in tumor's volumes were not
available. Tumors with no increase in its tumor volume were
deﬁned as stable. Tumor growth was deﬁned as an increase in
tumor size over a measurement interval. Tumor growth rate
was calculated as: (ﬁnal volume  initial volume)/follow-up
interval. Tumor quiescence was deﬁned as no tumor growth
over 1-year interval. De novo meningiomas were deﬁned as
tumors that were undetectable on the previous imaging.
2.3. Factors affecting tumor growth rate
Clinical and radiological features that might be related to
meningioma growth were recorded: age at ﬁrst symptoms of
NF2, sex, length of observation, tumor volume at diagnosis,
peritumoral edema, skull-base tumor location, number of
intracranial meningiomas and presence of non-vestibular
schwannomas and spinal tumors.
2.4. Statistical analysis
Statistical analyses were performed in STATISTICA version
10.0 (StatSoft Inc., 2011). Quantitative variables were charac-
terized by the arithmetic mean, standard deviation, median,
minimum and maximum values and 95% CI (conﬁdence
interval). Statistical signiﬁcance of differences between the
two groups was analyzed with t-Student-test or Mann–
Whitney U-test. Statistical signiﬁcance of differences between
more than two groups was tested by an F test (ANOVA) or
Kruskal–Wallis test. In the case of two variables associated
model t-Student-test or Wilcoxon-test were used. Chi-square
tests were used for categorical variables. Statistical signiﬁ-
cance was presumed p = 0.05.
3. Results
3.1. Patient and tumor characteristics
There were 19 women and 15 men in the entire cohort of NF2
patients. Characteristics of the patients and the comparison
between NF2 patients with intracranial meningiomas and
those without the lesions are given in Table 1. Among the 21
patients with meningiomas spinal ependymomas and non-
vestibular schwannomas were more frequently observed. We
found 118 intracranial meningiomas in 21 patients in our
series (mean 5.2  3.9 tumors/patient, range 1–16 tumors). 16
(76.2%) patients had multiple meningiomas. The most
common locations of meningioma were convexity (37.3%),
parasagittal and falx region (29.7%), and the skull base (27.1%).
In 5 patients extensive tumor growth was observed along the
parasagittal and falx region and convexity. MRI revealed
adjacent parenchymal edema in 8 tumors (7%). 8 meningiomas
in 7 patients were symptomatic. In 3 cases these tumors
produced the ﬁrst symptoms of the disease. In the other
5 cases meningiomas became symptomatic during the follow-
up interval. In a univariate analysis, it was found that with an
Table 1 – NF2 patients' characteristics.
Characteristic No. of patients (%) p value
Intracranial meningioma present
21 (61.8)
Intracranial meningioma absent
13 (38.2)
Female 12 (57.1) 7 (53.8) 0.56
Mean age at ﬁrst symptoms (SD)(years) 20.8 (11.2) 21.2 (5.5) 0.93
Bilateral vestibular schwannoma 18 (85.7) 13 (100) 0.22
Non-vestibular schwannoma 8 (38.1) 1 (7.7) 0.056
Spinal meningioma/schwannoma 17 (81) 7 (53.8) 0.098
Spinal ependymoma 10 (47.6) 1 (7.7) 0.017
SD – standard deviation. Values in bold indicate statistical signiﬁcance.
Table 2 – Prognostic factors for symptomatic intracranial
meningiomas in NF2 patients.
Prognostic factor p (univariate analysis)
Age at ﬁrst symptoms 0.949
Tumor volume 0.001
Length of observation 0.924
Number of tumors 0.898
Sex 0.773
Skull-base tumor location 0.032
Brain edema 0.001
Non-vestibular schwannoma present 0.463
Spinal ependymoma present 0.562
Spinal meningioma/schwannoma present 0.534
Values in bold indicate statistical signiﬁcance.
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and with the tumor location at the skull base (p = 0.032)
meningiomas are more likely to be symptomatic. These
factors, however, did not reach statistical signiﬁcance in
multivariate analysis (Table 2).Fig. 1 – Graph of the length of observation of i3.2. Natural growth rate of meningioma in NF2 patients
The mean length of radiological follow-up was 6.5  3.7 years
(range 2–16 years) (Fig. 1). 58 (49%) tumors demonstrated
growth during the follow-up period. The mean volume of
meningiomas at diagnosis was 3.4  5.8 cm3 (95%CI [2.4; 4.5],
range 0.1–39.2 cm3). The mean growth rate for all intracranial
meningiomas was 0.5  1.1 cm3/year (95%CI [0.3; 0.7], range 0–
8.4 cm3/year). The mean growth rate for growing meningiomas
was 1.1  1.4 cm3/year (95%CI [0.7; 1.4], range 0.2–8.4 cm3/
year). Comparing symptomatic and asymptomatic tumors, it
was found that the mean growth rate for symptomatic
meningiomas was signiﬁcantly higher than in asymptomatic
tumors (Mann–Whitney U-test Z = 4.58, p = 0.0001) (Table 3).
Univariate analysis revealed that tumor growth was
associated with a younger age at the onset of NF2-related
symptoms (p = 0.001), greater initial tumor volume (p = 0.013),
brain edema ( p = 0.005) and with the presence of intracranial
non-vestibular schwannoma (p = 0.042). Multivariate analysis
conﬁrmed that with increasing age of the ﬁrst symptoms of the
disease decreases the likelihood of tumor growth. Moreover,
multivariate analysis showed that the probability of tumorntracranial meningiomas in NF2 patients.
Table 3 – Tumor growth rate (cm3/year) for symptomatic
and asymptomatic meningiomas.
Tumor growth Asymptomatic
meningiomas
(110 cases)
Symptomatic
meningiomas
(8 cases)
p Value
Mean (SD) 0.3 (0.5) 3.7 (2.4) 0.0001
95%CI [0.2; 0.4] [1.7; 5.6]
Range 0.0–3.9 0.9–8.4
Median 0.0 3.5
Table 4 – Prognostic factors for growing intracranial
meningiomas in NF2 patients.
Prognostic factor p value
(univariate
analysis)
p value
(multivariate
analysis)
Age at ﬁrst symptoms 0.001 0.0001
Tumor volume 0.013 0.926
Length of observation 0.584 0.006
Number of tumors 0.147 0.959
Sex 0.830 0.203
Skull-base tumor location 0.178 -
Brain edema 0.005 0.001
Non-vestibular schwannoma
present
0.042 0.878
Spinal ependymoma present 0.352 0.157
Spinal meningioma/
schwannoma present
0.684 0.810
Values in bold indicate statistical signiﬁcance.
Table 6 – Prognostic factors for de novo intracranial
meningiomas in NF2 patients.
Prognostic factor p (univariate analysis)
Age at ﬁrst symptoms 0.555
Tumor volume 0.591
Length of observation 0.001
Number of tumors 0.033
Sex 0.506
Skull-base tumor location 0.070
Brain edema 0.172
Non-vestibular schwannoma present 0.003
Spinal ependymoma present 0.114
Spinal meningioma/schwannoma
present
0.415
Values in bold indicate statistical signiﬁcance.
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edema (Table 4).
Of 58 tumors that demonstrated growth, quiescent periods
were observed in 12 cases with the mean duration of quiescent
periods of 2.8  2.1 years (range 1–7 years). These tumors
displayed a saltatory pattern of growth characterized by
intervening periods of no tumor growth. Analysis revealed
that growing meningiomas with quiescent periods were
signiﬁcantly associated with the length of time of observation
(p = 0.0001) (Table 5).
3.3. Development of new tumors
At the end of follow-up 12 de novo meningiomas appeared in
6 patients. De novo meningiomas exhibited a signiﬁcantly
higher growth rate than other meningiomas (0.8  0.6 cm3/yearTable 5 – Prognostic factors for growing meningiomas with an
Prognostic factor Growing
meningiom
with quiesce
periods (12 pat
Mean age at ﬁrst symptoms (SD) (years) 19.91  8.14
Mean tumor growth rate (cm3/year) 1.07  0.97
Length of observation (years) 11.9  2.19 
Skull base location 4a
Brain edema 2a
SD – standard deviation.
a No. of patients.
Values in bold indicate statistical signiﬁcance.vs. 0.5  1.2 cm3/year, Mann–Whitney U-test Z = 3.61,
p = 0.0003) but did not require surgery more often than other
meningiomas (25% vs 17%, p = 0.83). These tumors were more
frequent in patients with intracranial non-vestibular schwan-
noma (p = 0.003) and with increasing length of meningioma
observation (p = 0.001). Interestingly, univariate analysis
revealed that the increase in the total number of intracranial
meningiomas decreases the likelihood of developing a new
tumor (p = 0.033) (Table 6). These factors, however, did not reach
statistical signiﬁcance in multivariate analysis.
3.4. Surgical treatment
21 (18%) tumors in 11 (52%) patients were resected during the
course of the study. In 8 of 21 cases (38%) the reason for tumor
resection was occurrence of clinical symptoms (neurological
deﬁcit in 4, epilepsy in 2, intracranial hypertension in 2). 11
asymptomatic tumors in the posterior fossa (5 of them were
growing meningiomas) have been removed by the way of
vestibular schwannoma resection. In one patient surgery was
performed due signiﬁcant de novo tumor growth in subse-
quent imaging studies. In another asymptomatic case surgery
was performed due to large tumor burden in the posterior
fossa. The main histological subtypes were ﬁbroblastic (10
cases), transitional (6 cases), and meningothelial (4 cases).
There was one atypical (WHO Grade II) meningioma. There
were no grade III meningioma cases. No operative death we
noted. Five patients experienced permanent postoperative
neurological deﬁcits (cranial nerves IX and X deﬁcits in 3,d without quiescent periods.
as
nt
ients)
Growing
meningiomas
without quiescent
periods (46 patients)
p value
 15.54  5.64 0.08
 1.1  1.53 0.93
5.7  2.92 0.0001
14a 0.55
6a 0.53
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I or grade II resection was achieved in all but one case. In this
case a tumor remnant was left in the cavernous sinus. Tumor
remnant was not eligible for adjuvant treatment. Among the
11 patients with meningiomas who underwent surgery the
mean postoperative clinical and radiological follow-up period
was 3.1 years (range 1.2–8.5 years). Three tumors in 3 patients
recurred during the follow-up period. One patient underwent
repeated surgery and the other two asymptomatic recurrent
tumors are being monitored.
4. Discussion
Neuroﬁbromatosis type 2 (NF2) is a heritable tumor predispo-
sition syndrome that leads to the development of multiple
intracranial tumors. Meningiomas are the second most
frequent tumor type in NF2 patients occurring in about half
of these patients. It is believed that meningiomas in NF2
patients are associated with disease severity [13] but little is
known about their natural history in these patients. In this
study we sought to evaluate tumor growth rate of NF2-
associated meningiomas and to deﬁne their inﬂuence on
neurological status of NF2 patients. Moreover we aim to assess
the risk and effectiveness of surgical treatment for this tumor
type. It should be noted, however, that there was no true
volumetric assessment of the tumors. Linear measurements
used in the study underestimate tumor growth rate compared
with volumetric measures. Moreover, limiting accuracy of
calculating tumor growth was lack of the evaluation of the
reliability of measurement method (interrater reliability).
The results of the present study tend to agree in several
respects with those of previously published works on natural
history of meningiomas in NF2 [18–20]. Meningioma growth
rates were found to be highly variable but only a small
proportion of tumors showed a signiﬁcant increase. Our study
conﬁrms that signiﬁcant proportion of meningiomas in NF2
patients demonstrated no tumor growth [13]. It is consistent
with the previous ﬁndings suggested that likewise in other
sporadic meningiomas tumors in NF2 patients exhibit varia-
tions in growth rates including periods of no tumor growth
[18,21–23]. In the study of Dirks et al. [18] 99% of intracranial
meningiomas exhibited growth and about 60% displayed
extended quiescent periods. They suggest that quiescence
described in some studies represents intervals between
growth periods and reported lack of tumor growth is solely
the result of too short follow-ups. Indeed, in our study the
likelihood of observing saltatory pattern of growth increased
with a longer duration of follow-up. Nevertheless these
observations require refraining from proactive treatment in
meningiomas of NF2 patients. Taken into account the
possibility of complications after surgery, tumor growth
should be conﬁrmed on serial imaging before considering
surgical treatment [20]. In contrast to vestibular schwannomas
where size matters in terms of hearing preservation, menin-
giomas do not require such a cautious approach and
differences in tumor size are not important. Hence, one can
afford to observe the tumor and make a decision about surgery
only after proving signiﬁcant tumor growth. Besides, based
on the obtained results, the risk of surgical treatment ofNF2-associated meningiomas seems to be comparable to
the risk in the event of sporadic meningiomas. Consensus
recommendations for current treatments in NF2 stated that
most meningiomas occur in surgically accessible locations and
surgery is considered the treatment of choice in cases that
require treatment [24]. Interestingly, in the opinion of Dirks
et al. [18] even demonstrated tumor growth is not an indication
for surgery. They thought that past tumor behavior does not
predict future growth and do not recommend surgery if the
tumor growth is not accompanied by clinical symptoms. As
meningiomas in NF2 exhibit differences in growth rates, even
among tumors within the same patient, it seems important to
determine the risk factors for their growth. Current study data
indicate that an increased growth rate is associated with
younger age at the onset of NF2-related symptoms, greater
initial tumor volume, brain edema and with the presence of
intracranial non-vestibular schwannoma. Goutagny et al. [20]
found that growing meningiomas were more frequent in
males and people up to 30 years old and were associated with
tumor edema and tumor size exceeding 25 mm. Similarly,
Dirks et al. [18] revealed more rapid tumor growth in young
patients but in contrast to the previous work they demon-
strated more rapid tumor growth related to female gender.
Histopathological ﬁndings in NF2-associated meningiomas
are ambiguous. Goutagny et al. [20] in contrast to other
published series [11,12,18] found that meningiomas in NF2
patients are not histologically more aggressive than their
sporadic counterparts. Our data corroborates these ﬁndings.
Contrary to previous studies, we found that de novo
meningiomas did not required surgery more frequently and
did not exhibited more aggressive histological behavior [20].
5. Conclusions
Meningiomas occur in about half NF2 patients. Many of them
exhibit slow growth and long remain asymptomatic, however,
those associated with early onset of NF2 symptoms and other
features of the disease severity should be monitored and in
case of clinical and radiological progression may require
surgical treatment. Despite the high prevalence of intracranial
meningiomas in NF2 patients these tumors do not constitute
a signiﬁcant clinical and surgical problem and observation of
asymptomatic tumors seems to be quite safe.
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